About

About Venture Valuation AG/Biotechgate Venture Valuation specializes in independent asset and company valuation of biotechnology, biopharma, life sciences and medical technology. Valuations are provided for fundraising, investment decision, portfolio valuations, in- and out-licensing, arbitration/fairness opinions and M&A. The company has developed "Biotechgate", which is business development and licensing database for the life sciences industry. Company Valuation: The Company Valuation Reports include a thorough assessment of the company by experienced professionals with expertise in the relevant fields as well as the following elements: • summary of key risk parameters and strengths of the company • outline of the crucial factors and value drivers for growth and further strategic development • assessment of the management, market, science, technology and products • analysis of the company’s business model and the company’s competitive environment • detailed calculation of the company’s financial value, using appropriate valuation methods Product Valuation: Venture Valuation offers detailed Product Valuation Reports of pre-clinical and clinical products in development that can serve as a basis for negotiations or to structure different deal scenarios. The Product Valuation includes: • detailed analysis of development costs, time lines, patient population, competing products, pricing and product life cycle • industry gold standard rNPV valuation methodology based on indication-specific attrition rates and the development stage • scenario and sensitivity analyses • analysis of the current value, and forecasts of the future value following the successful completion of key development milestones As an “add on” module and based on Venture Valuation’s deal database within Biotechgate, benchmarking deals can also be included to provide the client with a differentiated negotiation basis and comparable information.